226 related articles for article (PubMed ID: 33437214)
1. Over-expression of RALYL suppresses the progression of ovarian clear cell carcinoma through inhibiting MAPK and CDH1 signaling pathways.
Xia Y; Ye S; Yang Y; Liu Y; Tong G
Int J Med Sci; 2021; 18(3):785-791. PubMed ID: 33437214
[No Abstract] [Full Text] [Related]
2. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
Zhu C; Zhu J; Qian L; Liu H; Shen Z; Wu D; Zhao W; Xiao W; Zhou Y
BMC Cancer; 2021 Mar; 21(1):322. PubMed ID: 33766002
[TBL] [Abstract][Full Text] [Related]
3. CHD1L promotes EOC cell invasiveness and metastasis via the regulation of METAP2.
He WP; Guo YY; Yang GP; Lai HL; Sun TT; Zhang ZW; Ouyang LL; Zheng Y; Tian LM; Li XH; You ZS; Xie D; Yang GF
Int J Med Sci; 2020; 17(15):2387-2395. PubMed ID: 32922205
[TBL] [Abstract][Full Text] [Related]
4. Circ-PGAM1 promotes malignant progression of epithelial ovarian cancer through regulation of the miR-542-3p/CDC5L/PEAK1 pathway.
Zhang C; Li Y; Zhao W; Liu G; Yang Q
Cancer Med; 2020 May; 9(10):3500-3521. PubMed ID: 32167655
[TBL] [Abstract][Full Text] [Related]
5. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
6. Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix.
Ota Y; Koizume S; Nakamura Y; Yoshihara M; Takahashi T; Sato S; Myoba S; Ohtake N; Kato H; Yokose T; Miyagi E; Miyagi Y
Oncol Rep; 2021 Mar; 45(3):1023-1032. PubMed ID: 33650653
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
Wu JL; Zhao J; Zhang HB; Zuo WW; Li Y; Kang S
Gynecol Oncol; 2020 Oct; 159(1):270-276. PubMed ID: 32694063
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
[No Abstract] [Full Text] [Related]
10. Ovarian Clear Cell Carcinoma: From Morphology to Molecular Biology.
Improta G; Pettinato A; Høgdall E; Santeusanio G; Vatrano S; Fraggetta F; Zannoni GF
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):631-636. PubMed ID: 29629954
[TBL] [Abstract][Full Text] [Related]
11. lncRNA MIAT Regulates Cell Growth, Migration, and Invasion Through Sponging miR-150-5p in Ovarian Cancer.
Zhou S; Xu A; Song T; Gao F; Sun H; Kong X
Cancer Biother Radiopharm; 2020 Nov; 35(9):650-660. PubMed ID: 32186927
[No Abstract] [Full Text] [Related]
12. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway.
Zhao J; Liu HR
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3243-3252. PubMed ID: 31081076
[TBL] [Abstract][Full Text] [Related]
14. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
[TBL] [Abstract][Full Text] [Related]
15. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.
Sun T; Bi F; Liu Z; Yang Q
Aging (Albany NY); 2020 Jul; 12(13):13281-13296. PubMed ID: 32647070
[TBL] [Abstract][Full Text] [Related]
16. LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression.
Yao N; Sun JQ; Yu L; Ma L; Guo BQ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4642-4649. PubMed ID: 31210289
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of miR-130a-3p modulate ovarian epithelial carcinoma (OEC) cell development and could be a biomarker for OEC.
Alrashed MM; Ahmad M; Yongmei W; Xiuyeng W
J Reprod Immunol; 2021 Jun; 145():103310. PubMed ID: 33730656
[TBL] [Abstract][Full Text] [Related]
18. miRNA‑199b‑3p suppresses growth and progression of ovarian cancer via the CHK1/E‑cadherin/EMT signaling pathway by targeting ZEB1.
Wei L; He Y; Bi S; Li X; Zhang J; Zhang S
Oncol Rep; 2021 Feb; 45(2):569-581. PubMed ID: 33416170
[TBL] [Abstract][Full Text] [Related]
19. HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis.
Li X; Zhang NX; Ye HY; Song PP; Chang W; Chen L; Wang Z; Zhang L; Wang NN
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(10):4126-4135. PubMed ID: 31173282
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of ribosomal protein S6 suppresses proliferation, migration, and invasion in epithelial ovarian cancer.
Yang X; Xu L; Yang YE; Xiong C; Yu J; Wang Y; Lin Y
J Ovarian Res; 2020 Aug; 13(1):100. PubMed ID: 32862831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
